Literature DB >> 9282116

Telomeres and telomerase in normal and malignant haematopoietic cells.

K F Norrback1, G Roos.   

Abstract

The normal haematopoietic system harbours telomerase-competent cells with a capacity to upregulate the activity to notable levels in a telomere length-independent manner. Strong telomerase activity is found in progenitor stem cells and activated lymphocytes in vitro as well as in vivo, indicating that cells with high growth requirements can readily upregulate telomerase. Despite detection of telomerase activity, a gradual telomere erosion occurs in stem cells and lymphocytes, with significantly shortened telomeres at higher ages, a phenomenon that might be of importance for developing immunosenescence and exhausted haematopoiesis. In malignant haematopoietic disorders telomerase activity is a general finding with large differences in activity levels. The strongest telomerase expression has been shown in acute leukaemias and non-Hodgkin's lymphomas, especially high grade cases. There are indications that the level of activity might parallel tumour progression and be of prognostic relevance, but studies of larger patient materials are needed. An association between the cell cycle and telomerase activity exists, especially for normal haematopoietic cells, and induction of a differentiation programme in immortalised cell lines downregulates telomerase activity. The expression of telomerase activity seems to be regulated at different levels, since for immature bone marrow cells the level of activity seemed to parallel better the phenotype than the proliferation state. The frequent expression of telomerase in leukaemias and lymphomas makes these disorders interesting targets for future anti-telomerase therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9282116     DOI: 10.1016/S0959-8049(97)00059-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells.

Authors:  D Xu; N Popov; M Hou; Q Wang; M Björkholm; A Gruber; A R Menkel; M Henriksson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  A protein array screen for Kaposi's sarcoma-associated herpesvirus LANA interactors links LANA to TIP60, PP2A activity, and telomere shortening.

Authors:  Meir Shamay; Jianyong Liu; Renfeng Li; Gangling Liao; Li Shen; Melanie Greenway; Shaohui Hu; Jian Zhu; Zhi Xie; Richard F Ambinder; Jiang Qian; Heng Zhu; S Diane Hayward
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

3.  Regulation of telomerase activity by alternate splicing of human telomerase reverse transcriptase mRNA in a subset of neuroblastomas.

Authors:  M Krams; A Claviez; K Heidorn; G Krupp; R Parwaresch; D Harms; P Rudolph
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

4.  Telomere lengths and telomerase activity in dog tissues: a potential model system to study human telomere and telomerase biology.

Authors:  L Nasir; P Devlin; T Mckevitt; G Rutteman; D J Argyle
Journal:  Neoplasia       Date:  2001 Jul-Aug       Impact factor: 5.715

Review 5.  A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy.

Authors:  Robert H Vonderheide; Carl H June
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

6.  The regulation of telomerase in oncogenesis.

Authors:  D A Skvortzov; M P Rubzova; M E Zvereva; F L Kiselev; O A Donzova
Journal:  Acta Naturae       Date:  2009-04       Impact factor: 1.845

7.  Telomere length and telomerase activity in malignant lymphomas at diagnosis and relapse.

Authors:  K Remes; K F Norrback; R Rosenquist; C Mehle; J Lindh; G Roos
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

8.  Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications.

Authors:  M Hultdin; R Rosenquist; U Thunberg; G Tobin; K-F Norrback; A Johnson; C Sundström; G Roos
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640

9.  Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors.

Authors:  Gabriela M Baerlocher; Joshua Rusbuldt; Jacqueline Bussolari; Fei Huang
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.